Movement Alert｜Guardant Health Inc. Rises 5.07% in Regular Trading, UBS Report Highlights Liquid Biopsy Tailwinds

Market Focus03:03

On October 6, Guardant Health Inc. rose 5.07% in regular trading, trading at $186.87/share, with turnover of $161 million.

The intraday gains followed UBS analysis positioning Guardant as a direct beneficiary of AstraZeneca's failed Serena-4 trial, which reaffirmed biomarker-driven monitoring demand for its liquid biopsy platform. Recent catalysts include Evicore's coverage for Shield colorectal screening effective early next year and FDA approval for Guardant360 CDx as a companion diagnostic alongside novel breast cancer therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment